- Home
- PHGE vs SMSI Comparison
PHGE vs SMSI Comparison
Compare PHGE & SMSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- SMSI
- Stock Information
- Founded
- PHGE 2015
- SMSI 1982
- Country
- PHGE Israel
- SMSI United States
- Employees
- PHGE N/A
- SMSI N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- SMSI Computer Software: Prepackaged Software
- Sector
- PHGE Health Care
- SMSI Technology
- Exchange
- PHGE Nasdaq
- SMSI Nasdaq
- Market Cap
- PHGE 15.5M
- SMSI 15.3M
- IPO Year
- PHGE N/A
- SMSI 1995
- Fundamental
- Price
- PHGE $0.58
- SMSI $0.72
- Analyst Decision
- PHGE Strong Buy
- SMSI Strong Buy
- Analyst Count
- PHGE 1
- SMSI 1
- Target Price
- PHGE $15.00
- SMSI $5.00
- AVG Volume (30 Days)
- PHGE 397.5K
- SMSI 1.3M
- Earning Date
- PHGE 11-13-2025
- SMSI 11-12-2025
- Dividend Yield
- PHGE N/A
- SMSI N/A
- EPS Growth
- PHGE N/A
- SMSI N/A
- EPS
- PHGE N/A
- SMSI N/A
- Revenue
- PHGE N/A
- SMSI $18,658,000.00
- Revenue This Year
- PHGE N/A
- SMSI N/A
- Revenue Next Year
- PHGE N/A
- SMSI $59.48
- P/E Ratio
- PHGE N/A
- SMSI N/A
- Revenue Growth
- PHGE N/A
- SMSI N/A
- 52 Week Low
- PHGE $0.34
- SMSI $0.60
- 52 Week High
- PHGE $1.16
- SMSI $1.95
- Technical
- Relative Strength Index (RSI)
- PHGE 53.87
- SMSI 45.06
- Support Level
- PHGE $0.55
- SMSI $0.68
- Resistance Level
- PHGE $0.63
- SMSI $0.75
- Average True Range (ATR)
- PHGE 0.05
- SMSI 0.06
- MACD
- PHGE -0.00
- SMSI -0.01
- Stochastic Oscillator
- PHGE 35.85
- SMSI 14.90
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About SMSI Smith Micro Software Inc.
Smith Micro Software Inc is a provider of software solutions. It develops and markets wireless solutions for wireless service providers, mobile device and chipset manufacturers, and enterprise businesses. Its portfolio includes family safety software solutions to support families in the digital age and creating, sharing, and monetizing rich content, such as visual voice messaging, retail content display optimization and performance analytics on any product set. The company's only reportable segment is Wireless. Wireless segment includes the Family Safety (which includes SafePath), CommSuite, and ViewSpot families of products.